Detalhe da pesquisa
1.
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
Blood
; 139(8): 1135-1146, 2022 02 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34543383
2.
The therapeutic potential of bedside art observation in hematologic cancer inpatients: a randomized controlled pilot study.
Support Care Cancer
; 30(4): 3585-3592, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-35022885
3.
Stem cell homing: From physiology to therapeutics.
Stem Cells
; 38(10): 1241-1253, 2020 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32526037
4.
Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.
Biol Blood Marrow Transplant
; 26(12): 2335-2345, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32961375
5.
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.
Biol Blood Marrow Transplant
; 26(11): 2139-2146, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32781289
6.
Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors.
Biol Blood Marrow Transplant
; 26(6): 1210-1217, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32088366
7.
The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time.
Biol Blood Marrow Transplant
; 25(7): 1325-1330, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30716454
8.
Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.
Biol Blood Marrow Transplant
; 25(4): 699-711, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30423480
9.
Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors.
Haematologica
; 104(4): 844-854, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30381298
10.
Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less.
Biol Blood Marrow Transplant
; 24(1): 175-184, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28958894
11.
Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
Blood
; 127(5): 616-25, 2016 Feb 04.
Artigo
Inglês
| MEDLINE | ID: mdl-26637787
12.
Evolution of acute myelogenous leukemia stem cell properties after treatment and progression.
Blood
; 128(13): 1671-8, 2016 09 29.
Artigo
Inglês
| MEDLINE | ID: mdl-27421961
13.
Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers.
Biol Blood Marrow Transplant
; 22(3): 520-7, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26597080
14.
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.
Biol Blood Marrow Transplant
; 22(2): 248-257, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26327629
15.
Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers.
Biol Blood Marrow Transplant
; 21(10): 1830-8, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26116089
16.
Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells.
Br J Haematol
; 171(2): 205-209, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26084925
17.
Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells.
J Biol Chem
; 288(47): 33542-33558, 2013 Nov 22.
Artigo
Inglês
| MEDLINE | ID: mdl-24089526
18.
Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.
Biol Blood Marrow Transplant
; 20(2): 202-8, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24184335
19.
Modulation of selectin-mediated adhesion of flowing lymphoma and bone marrow cells by immobilized SDF-1.
Int J Mol Sci
; 15(9): 15061-72, 2014 Aug 27.
Artigo
Inglês
| MEDLINE | ID: mdl-25167133
20.
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
Blood Adv
; 8(2): 378-387, 2024 01 23.
Artigo
Inglês
| MEDLINE | ID: mdl-37871300